B. Mannargudi

发表

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

G. Giaccone, E. Szabo, S. Kummar, 2012, Clinical Cancer Research.

Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats.

M. Popović, J. Uetrecht, B. Mannargudi, 2006, Chemical research in toxicology.

Bioactivation of Minocycline to Reactive Intermediates by Myeloperoxidase, Horseradish Peroxidase, and Hepatic Microsomes: Implications for Minocycline-Induced Lupus and Hepatitis

D. McNally, J. Uetrecht, B. Mannargudi, 2009, Drug Metabolism and Disposition.

Microsoft Word-42454773-file00

J. Uetrecht, B. Mannargudi, David McNally, 2009 .

A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application

E. Kohn, Jung-Min Lee, H. Swaisland, 2014 .

Nevirapine hypersensitivity.

M. Popović, J. Uetrecht, B. Mannargudi, 2010, Handbook of experimental pharmacology.

Covalent binding of penicillamine to macrophages: implications for penicillamine-induced autoimmunity.

J. Uetrecht, B. Mannargudi, Jinze Li, 2009, Chemical research in toxicology.

Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash.

J. Uetrecht, B. Mannargudi, Ling Xu, 2008, Chemical research in toxicology.

A Study of the Specificity of Lymphocytes in Nevirapine-Induced Skin Rash

J. Uetrecht, B. Mannargudi, Xin Chen, 2009, Journal of Pharmacology and Experimental Therapeutics.

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

G. Giaccone, W. Zein, B. Houk, 2011, Clinical Cancer Research.

Engineering d-amino acid containing novel protease inhibitors using catalytic site architecture.

Liang Tong, Lakshmi P Kotra, E. Poduch, 2006, Bioorganic & medicinal chemistry.